Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Compared with the placebo group, the multivitamin group had significantly greater increases in serum 25(OH)D, vitamin B-12, and folate (Supplementary Figures 5 to 7; Supplementary Results).
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Double-blind reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial
Source: Article title.
We performed a randomized, double-blind, placebo-controlled, 2-by-2 factorial trial of a daily MVM and cocoa extract for prevention of cancer and cardiovascular disease (CVD) among 21,442 US adults (12,666 women aged ≥65 y and 8776 men aged ≥60 y) free of major CVD and recently diagnosed cancer.
Source: Abstract.
We performed a randomized, double-blind, placebo-controlled, 2-by-2 factorial trial of a daily MVM and cocoa extract for prevention of cancer and cardiovascular disease (CVD) among 21,442 US adults (12,666 women aged ≥65 y and 8776 men aged ≥60 y) free of major CVD and recently diagnosed cancer.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial
Randomised controlled trial · The American Journal of Clinical Nutrition · 2022
Original publication title
Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial
© The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
The study objective was to determine if a daily MVM decreases total invasive cancer among older adults.
Source: ObjectivesAbstract: What methods does the paper describe?
We performed a randomized, double-blind, placebo-controlled, 2-by-2 factorial trial of a daily MVM and cocoa extract for prevention of cancer and cardiovascular disease (CVD) among 21,442 US adults (12,666 women aged ≥65 y and 8776 men aged ≥60 y) free of major CVD and recently diagnosed cancer. The intervention phase was from June 2015 through December 2020. This article reports on the MVM intervention. Participants were randomly assigned to daily MVM or placebo. The primary outcome was total invasive cancer, excluding nonmelanoma skin cancer.
Secondary outcomes included major site-specific cancers, total CVD, all-cause mortality, and total cancer risk among those with a baseline history of cancer.
Source: MethodsAbstract: Results
During a median follow-up of 3.6 y, invasive cancer occurred in 518 participants in the MVM group and 535 participants in the placebo group (HR: 0.97; 95% CI: 0.86, 1.09; P = 0.57). We observed no significant effect of a daily MVM on breast cancer (HR: 1.06; 95% CI: 0.79, 1.42) or colorectal cancer (HR: 1.30; 95% CI: 0.80, 2.12). We observed a protective effect of a daily MVM on lung cancer (HR: 0.62; 95% CI: 0.42, 0.92). The composite CVD outcome occurred in 429 participants in the MVM group and 437 participants in the placebo group (HR: 0.98; 95% CI: 0.86, 1.12).
MVM use did not significantly affect all-cause mortality (HR: 0.93; 95% CI: 0.81, 1.08). There were no safety concerns.
Source: ResultsAbstract: Conclusions
A daily MVM supplement, compared with placebo, did not significantly reduce the incidence of total cancer among older men and women. Future studies are needed to determine the effects of MVMs on other aging-related outcomes among older adults. This trial is registered at www.clinicaltrials.gov as NCT02422745.
Source: ConclusionsAuthors’ abstract
ABSTRACT
Background
Although older adults commonly take multivitamin-multimineral (MVM) supplements to promote health, evidence on the use of daily MVMs on invasive cancer is limited.
Objectives
The study objective was to determine if a daily MVM decreases total invasive cancer among older adults.
Methods
We performed a randomized, double-blind, placebo-controlled, 2-by-2 factorial trial of a daily MVM and cocoa extract for prevention of cancer and cardiovascular disease (CVD) among 21,442 US adults (12,666 women aged ≥65 y and 8776 men aged ≥60 y) free of major CVD and recently diagnosed cancer. The intervention phase was from June 2015 through December 2020. This article reports on the MVM intervention. Participants were randomly assigned to daily MVM or placebo. The primary outcome was total invasive cancer, excluding nonmelanoma skin cancer.
Secondary outcomes included major site-specific cancers, total CVD, all-cause mortality, and total cancer risk among those with a baseline history of cancer.
Results
During a median follow-up of 3.6 y, invasive cancer occurred in 518 participants in the MVM group and 535 participants in the placebo group (HR: 0.97; 95% CI: 0.86, 1.09; P = 0.57). We observed no significant effect of a daily MVM on breast cancer (HR: 1.06; 95% CI: 0.79, 1.42) or colorectal cancer (HR: 1.30; 95% CI: 0.80, 2.12). We observed a protective effect of a daily MVM on lung cancer (HR: 0.62; 95% CI: 0.42, 0.92). The composite CVD outcome occurred in 429 participants in the MVM group and 437 participants in the placebo group (HR: 0.98; 95% CI: 0.86, 1.12).
MVM use did not significantly affect all-cause mortality (HR: 0.93; 95% CI: 0.81, 1.08). There were no safety concerns.
Conclusions
A daily MVM supplement, compared with placebo, did not significantly reduce the incidence of total cancer among older men and women. Future studies are needed to determine the effects of MVMs on other aging-related outcomes among older adults. This trial is registered at www.clinicaltrials.gov as NCT02422745.
Publication and source details
Original title: Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial
Howard D Sesso; Pamela M Rist; Aaron K Aragaki; Susanne Rautiainen; Lisa G Johnson; Georgina Friedenberg; Trisha Copeland; Allison Clar; Samia Mora; M Vinayaga Moorthy; Ara Sarkissian; Jean Wactawski-Wende; Lesley F Tinker; William R Carrick; Garnet L Anderson; JoAnn E Manson; COSMOS Research Group MansonJoAnn ESessoHoward DRistPamela MLagerstromSusanne RautiainenBassukShari SWangLuHazraAditiGibsonHeikeLeBoffMeryl SMoraSamiaOkerekeOlivia ITobiasDeirdre KCookNancy RChandlerPaulette DChristenWilliamFriedenbergGeorginaCopelandTrishaHannaJasmahClarAllisonD'AgostinoDeniseVinayagamoorthyManickavasagarGibsonHeikeKimEunjungVan DenburghMartinKotlerGregoryLiChunyingBubesVadimSarkissianAraSmithDougPereiraEduardo COkekeMelvynRocheEliseBatesDavidRidgeClairePhillipsAlexandraSalvoBrielleWilsonAnnaleeHallLeahBaezJimaldySimYoung-HwanCardosoHayaraSenorGabrielRudnickiConnorHuynhHanhNguyenVivianeTerrellNicholasHolmanBeth AWalterJosephJohnsonLisa FieldsCasarellaAmyO'ConnellJuliaChristenWilliamLagerstromSusanne RautiainenDjousséLucChandlerPaulette DHazraAditiTobiasDeidre KFarukhiZareen MWangLuZhangXuehongBreenKennethMenjin JrGeorge VRodriguezRolandoCurryShamikhahMoraSamiaArsenaultLeahSolanoOlubunmiWeinbergAlisonCoatesJenniferKilroeMatthewZernickeLincolnHassonKatelynMatthewKarenMoraSamiaPfefferChrisDuszlakJulieBatesDavidGuzmanVincentFalconJosueRomeroAlexKupetsHenryCortezFrankLeSuerJames CHrbekAndreaBowesEileenQuinnPhilomenaMeleMeganAndersonGarnet LJohnsonLisaTinkerLeslie FAragakiAaron KHerndonMeganMannSue LPettingerMaryHuntRebecca PCarrickBillSzyperskiKateProulx-BurnsLoriBurrowsElizabethLimacherMarianHsiaJudithAsaithambiGaneshKhanMuhibNagarajaNandakumarOcavaLenore CWoldJanaSilverBrianConnellyStephanieVan LomGretchenGarvidaCrisHightowerKathySpauldingPatriciaLinWeiSchoenbergJennyOleePattiCohenLawrence SColtonTheodoreHendersonI CraigHulleyStephenLichtensteinAlice HPassamaniEugene RSillimanRebecca AWengerNanetteLudlamShari ESchroeterHagenFareMichaelOttawaniJavierKwik-UribeCatherineArnaizCassandraCostanzaAnnGreeneJohnHennesseyPaulVadlamaniSarmaKarmsettyMallikMartiniPaulvan KlinkenJan-WillemShahAlpaSternLori
The American Journal of Clinical Nutrition · 2022
Address correspondence to HDS (e-mail: hsesso@bwh.harvard.edu)© The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition.2022https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. COSMOS AG050657AG071611EY025623HL157665 National Institutes of Health10.13039/100000002 National Heart, Lung, and Blood Institute10.13039/100000050 U.S. Department of Health and Human Services10.13039/100000016 75N92021D0000175N92021D0000275N92021D0000375N92021D0000475N92021D00005Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T09:02:35.360197+00:00
DOI: 10.1093/ajcn/nqac056 · PMC9170475